connbio | Abstract Finder

Abstract Number: 1018 – Differentiating between MM like Smoldering Myeloma (SMM) and Non-Progressor SMM

Presenter: Mehmet K. Samur, PhDSession: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Genes, Cells and Algorithms: Novel Methods of Predicting Progression in MGUS and SMMDate & Time: Monday, December 9, 2024...

Abstract Number: 1017 – Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants

Presenter: Floris Chabrun, PhD, PharmDSession: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Genes, Cells and Algorithms: Novel Methods of Predicting Progression in MGUS and SMMDate & Time: Monday, December 9,...

Abstract Number: 936 – Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Presenter: Doris K. Hansen, MDSession: 907. Outcomes Research: Plasma Cell Disorders: Bispecific Antibodies and CAR-T Therapies in Myeloma-The Yin and Yang of Powerful TherapiesDate & Time: Monday, December 9, 2024 4:00 PM–4:15 PMLocation: San Diego Ballroom AB...

Abstract Number: 934 – Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Presenter: Oren Pasvolsky, MDSession: 907. Outcomes Research: Plasma Cell Disorders: Bispecific Antibodies and CAR-T Therapies in Myeloma-The Yin and Yang of Powerful TherapiesDate & Time: Monday, December 9, 2024 3:30 PM–3:45 PMLocation: San Diego Ballroom AB...

Abstract Number: 933 – Real-World Characteristics and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab Step-up Doses in Academic Vs. Community Settings

Presenter: Adeel M Khan, MD, MS, MPHSession: 907. Outcomes Research: Plasma Cell Disorders: Bispecific Antibodies and CAR-T Therapies in Myeloma-The Yin and Yang of Powerful TherapiesDate & Time: Monday, December 9, 2024 3:15 PM–3:30 PMLocation: San Diego...

« Older Entries

Next Entries »

Abstract Number: 1018 – Differentiating between MM like Smoldering Myeloma (SMM) and Non-Progressor SMM

Abstract Number: 1017 – Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants

Abstract Number: 936 – Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Abstract Number: 934 – Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Abstract Number: 933 – Real-World Characteristics and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab Step-up Doses in Academic Vs. Community Settings

Recent Posts

Recent Comments

Archives

Categories

Meta